ADVA
19.5.2020 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso is using its cloud-native security solution, ConnectGuard™ Cloud, to offer secure managed services. The virtualized encryption technology will give dacoso’s customers comprehensive data protection in cloud environments. With unprecedented scale and efficiency, dacoso will be able to roll out secure connectivity within minutes, safeguarding private, public, and edge/branch clouds at Layers 2, 3 and 4. Managed centrally in dacoso’s network by ADVA’s Ensemble Controller , the VPN services offer a major boost to the region’s businesses as they look to reduce costs and enhance flexibility by migrating more of their data and applications to the cloud. Now dacoso’s enterprise customers can harness the latest cloud tools while ensuring data integrity, regulatory compliance and true peace of mind for their end users.
“We’re excited to be offering our customers the comprehensive protection of ADVA’s ConnectGuard™ Cloud technology. For many of them, total cloud security is key to their business needs. By providing strong and flexible data protection in virtual environments, we’re enabling our customers to realize their full potential by accessing cloud applications with complete peace of mind,” said Karsten Geise, head of business and product development, dacoso. “We’re convinced by the robust security and performance benefits of ConnectGuard Cloud™. So much so that we’re already harnessing the solutions to protect our own branch and cloud locations. We understand its power to protect mission-critical data while also reducing costs and enhancing network utilization.”
Implemented entirely in software, ADVA’s ConnectGuard™ Cloud is a highly scalable, standards-compliant encryption solution that provides hybrid and multi-cloud environments with the ultimate defense against cyber threats. It enables dacoso to offer its customers high-performance, transport-layer-independent security with none of the performance issues of IPSec-based technologies. As a far more efficient and cost-effective alternative to hardware security appliances, ConnectGuard™ Cloud empowers dacoso’s customers to extend encryption to remote workers and branch offices by leveraging low-cost uCPE platforms. What’s more, with zero-touch provisioning, dacoso can roll out fully secured cloud connectivity almost instantly without any manual configuration.
“Our partnership with dacoso is great news for a huge number of enterprises across this region who are currently undergoing their digital transformation. With more and more of dacoso’s customers moving their workloads to cloud environments, our ConnectGuard™ Cloud technology provides the ideal way to ensure privacy and data integrity while keeping cost and complexity low,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “As a virtualized encryption solution with zero-touch provisioning and automated key management, our ConnectGuard™ Cloud is the most readily scalable option available. It improves operational simplicity and latency performance compared to appliance-based encryption methods. What’s more, it keeps latency at its lowest levels – a key requirement for many emerging cloud applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Virtual Networking and Cyber Security. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso’s services comprise, among other, optical data links encrypted to satisfy BSI requirements (Federal Office for Information Security), a certified Security Operations Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen near Frankfurt a.M. with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom